Compare · Head-to-head
Thymosin Alpha-1 vs Thymosin Beta-4.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Thymosin Alpha-1, then use the table to confirm fit.
Thymosin Alpha-1 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Thymosin Alpha-1
Immunomodulatory peptide approved in various countries with broader clinical literature than most RUO peptides.
01 · At a glance
| Decision factor | Thymosin Alpha-1 | Thymosin Beta-4 |
|---|---|---|
| Primary fit | longevity & anti-aging and immune support comparisons | tissue repair & recovery and immune support comparisons |
| Evidence | Tier B | Tier B-C |
| Risk | medium | med-high |
| Experience level | intermediate | intermediate |
| Budget tier | mid | mid |
| Administration route | subcutaneous | topical, subcutaneous |
02 · Use case & timing
| Decision factor | Thymosin Alpha-1 | Thymosin Beta-4 |
|---|---|---|
| Goal fit | Longevity & Anti-Aging, Immune Support | Tissue Repair & Recovery, Immune Support |
| What users compare it for | Immune modulation; clinical literature broader than most RUO peptides. | Ophthalmic: improved corneal epithelial healing. Systemic: wound healing signals in preclinical models. |
| Onset timeline | Immune biomarkers and clinical outcomes over weeks to months. | Corneal healing studies: days to weeks; systemic repair claims are less well-timed. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | Thymosin Alpha-1 | Thymosin Beta-4 |
|---|---|---|
| Adverse effects | Generally tolerable in clinical contexts; clinician oversight required. | Human ophthalmic safety reported as acceptable in trials; systemic safety requires caution. |
| Contraindications | Potential interactions with immunotherapies/vaccines. | Limited formal contraindication data. |
| Interaction notes | Potential interactions with immunotherapies/vaccines; do not provide combination advice. | Limited formal interaction studies; treat as unknown outside studied settings. |
| Regulatory status | Investigational | Investigational |
| FDA flag | FDA status unclear | FDA compounding caution |
| WADA status | Not listed | WADA S2 |
04 · Age & monitoring
| Decision factor | Thymosin Alpha-1 | Thymosin Beta-4 |
|---|---|---|
| Supported age ranges | 35-44, 45-54, 55-64, 65+ | No age guidance yet |
| Life-stage note | Age fit improves later in life because immune-support logic becomes more relevant as immunosenescence rises. | Not yet documented |
| Monitoring burden | medium | Not specified |
| Follow-up cadence | Periodic reassessment every few months, especially if health context is complex. | Not yet documented |
05 · Cost & sourcing
| Decision factor | Thymosin Alpha-1 | Thymosin Beta-4 |
|---|---|---|
| Typical cycle cost | $79.98 | $192.00 |
| Estimated monthly cost | $53.32 | $96.00 |
| Cost confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | Thymosin Alpha-1 | Thymosin Beta-4 |
|---|---|---|
| Tracked vendor listings | 1 listing | 1 listing |
| Sourcing note | Tracked product pages are available, which makes it easier to review the listing before you click out. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.